Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BGE 102

Next Previous
Drug Profile

BGE 102

Alternative Names: BGE-102

Latest Information Update: 08 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioAge Labs
  • Class Anti-inflammatories; Cardiovascular therapies; Eye disorder therapies; Obesity therapies; Small molecules
  • Mechanism of Action NLRP3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cardiovascular disorders; Obesity
  • Preclinical Diabetic macular oedema

Most Recent Events

  • 24 Mar 2026 Pharmacokinetics and Pharmacodynamics data from phase-I trial in Cardiovascular disorders and Obesity released by BioAge Labs
  • 24 Mar 2026 BioAge Labs plans to initiate phase III registration study by the end of 2027
  • 20 Jan 2026 Preclinical trials in Diabetic macular oedema in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top